

Table SII. Association between concordance of *BRAF* or *NRAS* mutational profiles with clinical characteristics of patients and metastases

	All patients	<i>BRAF</i> status			<i>NRAS</i> status		
		Discordance	Concordance	<i>p</i> -value	Discordance	Concordance	<i>p</i> -value
<i>Characteristics of patients</i>							
Sex	<i>n</i> =30	<i>n</i> =4	<i>n</i> =26		<i>n</i> =4	<i>n</i> =26	
Male	17 (56.7)	2 (50.0)	15 (57.7)	0.77	3 (75)	14 (53.8)	0.43
Female	13 (43.3)	2 (50.0)	11 (42.3)		1 (25)	12 (46.2)	
Synchronous primary/metastases							
No	9 (30)	2 (50.0)	7 (27.0)	0.48	0	9 (34.6)	0.18
Yes	17 (56.6)	2 (50.0)	15 (57.7)		3 (75)	14 (53.8)	
<i>Characteristics of metastases</i>	<i>n</i> =39	<i>n</i> =4	<i>n</i> =35		<i>n</i> =5	<i>n</i> =34	
Anatomical location of metastases							
Lymph nodes	23 (59)	2 (50)	21 (60)	0.56	4 (80)	19 (56)	0.73
Skin	11 (28.2)	1 (25)	10 (28.6)		1 (20)	10 (29.4)	
Visceral	3 (7.7)	1 (25)	2 (5.7)		0	3 (8.8)	
Brain	2 (5.1)	0	2 (5.7)		0	2 (5.8)	